FutureChem said it has received the final report for the U.S. phase 1 clinical trial of FC705, a prostate cancer treatment candidate.

The University of Maryland Medical Center and five other centers conducted the phase 1 trial in the U.S.

According to the results, all participating patients who received FC705 showed decreased PSA (Prostate-Specific Antigen) levels, an indicator of prostate cancer treatment.

Half of these patients experienced a reduction of more than 50 percent in PSA levels, aligning with results from the phase 1 clinical trial conducted in Korea.

Notably, FutureChem stressed that one patient exhibited an impressive 88 percent drop in PSA levels.

Safety evaluations revealed no dose-limiting toxicity (DLT), with only minor adverse reactions noted.

"We are encouraged by the fact that the U.S. trial showed a higher PSA 50 response than Novartis' PSMA-617, despite dosing the patient only once," a FutureChem official said. "We're also optimistic about upcoming Phase 2a clinical outcomes."

FutureChem administers FC705 in the U.S. Phase 2a and Korea Phase 2 clinical trials.

The regimen involves administering a 100mCi dosage every eight weeks for six cycles.

It aims to assess the drug's safety and efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

FutureChem also stressed that it is in talks to transfer the prostate cancer drug FC705 technology to China and intends to finalize key negotiation points by the end of September.